Literature DB >> 12153285

Design, synthesis, and evaluation of 6-carboxyalkyl and 6-phosphonoxyalkyl derivatives of 7-oxo-8-ribitylaminolumazines as inhibitors of riboflavin synthase and lumazine synthase.

Mark Cushman1, Donglai Yang, Stefan Gerhardt, Robert Huber, Markus Fischer, Klaus Kis, Adelbert Bacher.   

Abstract

A series of 6-carboxyalkyl and 6-phosphonoxyalkyl derivatives of 7-oxo-8-D-ribityllumazine were synthesized as inhibitors of both Escherichia coli riboflavin synthase and Bacillus subtilis lumazine synthase. The compounds were designed to bind to both the ribitylpurine binding site and the phosphate binding site of lumazine synthase. In the carboxyalkyl series, maximum activity against both enzymes was observed with the 3'-carboxypropyl compound 22. Lengthening or shortening the chain linking the carboxyl group to the lumazine by one carbon resulted in decreased activity. In the phosphonoxyalkyl series, the 3'-phosphonoxypropyl compound 33 was more potent than the 4'-phosphonoxybutyl derivative 39 against lumazine synthase, but it was less potent against riboflavin synthase. Molecular modeling suggested that the terminal carboxyl group of 6-(3'-carboxypropyl)-7-oxo-8-D-ribityllumazine (22) may bind to the side chains of Arg127 and Lys135 of the enzyme. A hypothetical molecular model was also constructed for the binding of 6-(2'-carboxyethyl)-7-oxolumazine (15) in the active site of E. coli riboflavin synthase, which demonstrated that the active site could readily accommodate two molecules of the inhibitor.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12153285     DOI: 10.1021/jo0201631

Source DB:  PubMed          Journal:  J Org Chem        ISSN: 0022-3263            Impact factor:   4.354


  6 in total

1.  Synthetic (±)-axinellamines deficient in halogen.

Authors:  Hui Ding; Andrew G Roberts; Patrick G Harran
Journal:  Angew Chem Int Ed Engl       Date:  2012-03-19       Impact factor: 15.336

Review 2.  Recognition of Vitamin B Precursors and Byproducts by Mucosal Associated Invariant T Cells.

Authors:  Sidonia B G Eckle; Alexandra J Corbett; Andrew N Keller; Zhenjun Chen; Dale I Godfrey; Ligong Liu; Jeffrey Y W Mak; David P Fairlie; Jamie Rossjohn; James McCluskey
Journal:  J Biol Chem       Date:  2015-10-14       Impact factor: 5.157

3.  T-cell activation by transitory neo-antigens derived from distinct microbial pathways.

Authors:  Alexandra J Corbett; Sidonia B G Eckle; Richard W Birkinshaw; Ligong Liu; Onisha Patel; Jennifer Mahony; Zhenjun Chen; Rangsima Reantragoon; Bronwyn Meehan; Hanwei Cao; Nicholas A Williamson; Richard A Strugnell; Douwe Van Sinderen; Jeffrey Y W Mak; David P Fairlie; Lars Kjer-Nielsen; Jamie Rossjohn; James McCluskey
Journal:  Nature       Date:  2014-04-02       Impact factor: 49.962

4.  A novel lumazine synthase inhibitor derived from oxidation of 1,3,6,8-tetrahydroxy-2,7-naphthyridine to a tetraazaperylenehexaone derivative.

Authors:  Yanlei Zhang; Boris Illarionov; Adelbert Bacher; Markus Fischer; Gunda I Georg; Qi-Zhuang Ye; David Vander Velde; Phillip E Fanwick; Yunlong Song; Mark Cushman
Journal:  J Org Chem       Date:  2007-03-10       Impact factor: 4.354

5.  Structural study and thermodynamic characterization of inhibitor binding to lumazine synthase from Bacillus anthracis.

Authors:  Ekaterina Morgunova; Boris Illarionov; Sabine Saller; Aleksander Popov; Thota Sambaiah; Adelbert Bacher; Mark Cushman; Markus Fischer; Rudolf Ladenstein
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-08-13

6.  MR1 displays the microbial metabolome driving selective MR1-restricted T cell receptor usage.

Authors:  Melanie J Harriff; Curtis McMurtrey; Cara A Froyd; Haihong Jin; Meghan Cansler; Megan Null; Aneta Worley; Erin W Meermeier; Gwendolyn Swarbrick; Aaron Nilsen; Deborah A Lewinsohn; William Hildebrand; Erin J Adams; David M Lewinsohn
Journal:  Sci Immunol       Date:  2018-07-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.